Squarepoint’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-71,367
| Closed | -$293K | – | 3618 |
|
|
2022
Q1 | $293K | Sell |
71,367
-80,239
| -53% | -$291K | ﹤0.01% | 2288 |
|
|
2021
Q4 | $541K | Sell |
151,606
-73,443
| -33% | -$257K | ﹤0.01% | 2088 |
|
|
2021
Q3 | $819K | Buy |
225,049
+97,989
| +77% | +$396K | ﹤0.01% | 1680 |
|
|
2021
Q2 | $554K | Buy |
+127,060
| New | +$518K | ﹤0.01% | 2053 |
|
|
2021
Q1 | – | Sell |
-15,339
| Closed | -$61K | – | 3816 |
|
|
2020
Q4 | $61K | Sell |
15,339
-10,361
| -40% | -$33.5K | ﹤0.01% | 2785 |
|
|
2020
Q3 | $69K | Sell |
25,700
-155,904
| -86% | -$431K | ﹤0.01% | 2336 |
|
|
2020
Q2 | $499K | Buy |
181,604
+34,068
| +23% | +$95.1K | 0.01% | 1318 |
|
|
2020
Q1 | $348K | Sell |
147,536
-127,317
| -46% | -$433K | 0.01% | 1228 |
|
|
2019
Q4 | $1.29M | Buy |
274,853
+243,244
| +770% | +$995K | 0.01% | 1181 |
|
|
2019
Q3 | $106K | Buy |
+31,609
| New | +$104K | ﹤0.01% | 2183 |
|
|
2016
Q3 | – | Sell |
-61,900
| Closed | -$65K | – | 1343 |
|
|
2016
Q2 | $65K | Buy |
+61,900
| New | +$59.8K | ﹤0.01% | 1007 |
|
|
2016
Q1 | – | Sell |
-57,400
| Closed | -$69K | – | 1533 |
|
|
2015
Q4 | $69K | Buy |
+57,400
| New | +$79.9K | 0.01% | 1171 |
|
Other funds holding ATRS
Squarepoint's ATRS Position: Q2 2022 in Review
Squarepoint sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 71,367 shares — an estimated $293K sold.
Squarepoint first reported a position in ATRS in Q4 2015 and held it in 12 quarters. The position peaked at $1.29M in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Squarepoint reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Squarepoint sold 71,367 Antares Pharma, Inc. shares in Q2 2022, an estimated $293K.
- Squarepoint first reported a position in Antares Pharma, Inc. in Q4 2015 and held it in 12 quarters.
- Squarepoint's Antares Pharma, Inc. position peaked at $1.29M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Squarepoint's 13F filing for Q2 2022, filed 15 Aug 2022.